bioAffinity Technologies, Inc.

NasdaqCM:BIAF Stock Report

Market Cap: US$8.4m

bioAffinity Technologies Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for bioAffinity Technologies.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth25.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Analysis Article • Mar 05

Here's Why bioAffinity Technologies (NASDAQ:BIAF) Must Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Sep 28

bioAffinity Technologies receives ~$7.7M from exercise of warrants

bioAffinity Technologies (NASDAQ:BIAF) received ~$7.7M from the exercise of its tradeable and non-tradable warrants issued as part of the Sep. 6 public offering of securities. A total of 725,576 tradeable warrants at $7.35 per share and 310,910 non-tradable warrants at $7.656 per share were exercised. Separately, the company had received ~$7.9M in gross proceeds from the underwritten public offering of 1,282,600 units. The proceeds are intended to be used to expand existing operations, for the commercialization of its CyPath Lung test and regulatory approvals and research and development of additional diagnostics and cancer therapeutics. It may also be used for working capital and general corporate purposes. Shares were trading +52.36% pre-market. Source: Press Release
Seeking Alpha • Sep 14

BioAffinity stock jumps 42% after peer-reviewed data on lung test

Newly IPO’ed biotech BioAffinity Technologies, Inc. (NASDAQ:BIAF) added ~42% in the morning hours Wednesday after the company announced the peer-reviewed publication of data on flow cytometry, a method it uses in its CyPath Lung noninvasive test. As published in the journal PLOS ONE, the research highlights high-throughput flow cytometry analysis of sputum. Results support the use of sputum analysis through flow cytometry as the basis of high-throughput diagnostic tests to evaluate lung health. “In the paper, we describe an innovative and highly efficient method to analyze sputum for the presence of lung cancer, with the potential to focus on other diseases such as COPD and asthma,” BIAF Chief Executive Maria Zannes noted. BIAF went public early this month, raising $7.8M in gross proceeds.

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as bioAffinity Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:BIAF - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20266-16N/AN/AN/A
12/31/20256-15-9-9N/A
9/30/20257-15-9-8N/A
6/30/20258-12-8-8N/A
3/31/20259-10-7-7N/A
12/31/20249-9-7-7N/A
9/30/20249-8-7-7N/A
6/30/20247-9-7-7N/A
3/31/20245-8-7-7N/A
12/31/20233-8-6-6N/A
9/30/20230-7-6-6N/A
6/30/20230-10-6-6N/A
3/31/20230-8-5-5N/A
12/31/20220-8-4-4N/A
9/30/20220-12-3-3N/A
6/30/20220-9-2-2N/A
3/31/2022N/A-7-2-2N/A
12/31/2021N/A-6-2-2N/A
9/30/2021N/A-3-2-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BIAF's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if BIAF's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if BIAF's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if BIAF's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if BIAF's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BIAF's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/16 03:19
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

bioAffinity Technologies, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anthony VendettiMaxim Group